AHA shares proposals to lower Medicare drug prices with Congress
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program.
Related News Articles
Headline
The federal government shutdown is expected to continue into next week as the Senate adjourned Oct. 9 after failing to pass spending legislation; senators plan…
Headline
The AHA provided a statement of record to the Senate Special Committee on Aging for a hearing Oct. 8 on the pharmaceutical and medical device supply chains.…
Headline
The federal government shutdown will continue as the Senate Oct. 3 failed to adopt a government funding deal. The latest attempt to pass the House-passed…
Headline
The federal government shut down Oct. 1 following a failed Senate vote on the House-passed continuing resolution to fund the government by midnight Sept. 30.…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The AHA Sept. 29 asked the Trump administration to provide exemptions for health care personnel from the proclamation issued Sept. 19 announcing changes to the…